News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
480 Results
Type
Article (65)
Press Release (415)
Section
Business (186)
Deals (45)
Drug Delivery (1)
Drug Development (111)
FDA (10)
Job Trends (11)
News (297)
Policy (19)
Tag
Academia (2)
Alliances (34)
Antibody-drug conjugate (ADC) (1)
Approvals (10)
Bankruptcy (1)
Best Places to Work (6)
Cell therapy (1)
Clinical research (66)
Collaboration (1)
COVID-19 (3)
C-suite (1)
Duchenne muscular dystrophy (4)
Earnings (83)
Events (126)
FDA (10)
Gene therapy (6)
GLP-1 (1)
Government (2)
Healthcare (3)
Immunology and inflammation (1)
Infectious disease (3)
Intellectual property (1)
IPO (34)
Job creations (4)
Layoffs (2)
Legal (2)
Mergers & acquisitions (11)
Neurodegenerative disease (1)
Neuroscience (1)
NextGen Class of 2024 (7)
Non-profit (8)
Northern California (1)
Opinion (1)
Patents (2)
People (52)
Phase I (45)
Phase II (54)
Phase III (12)
Pipeline (1)
Podcasts (1)
Policy (2)
Preclinical (7)
Press Release (1)
Rare diseases (2)
Real estate (4)
Regulatory (16)
Startups (4)
The Weekly (1)
United States (8)
Date
Today (1)
Last 7 days (3)
Last 30 days (5)
Last 365 days (49)
2024 (47)
2023 (54)
2022 (70)
2021 (75)
2020 (66)
2019 (46)
2018 (47)
2017 (19)
2016 (13)
2015 (25)
2014 (10)
2013 (5)
2012 (2)
2011 (1)
Location
Asia (8)
Australia (1)
California (1)
Europe (31)
Florida (1)
Georgia (3)
Massachusetts (2)
New Jersey (1)
Northern California (1)
480 Results for "regenxbio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for 2026—potentially posing a threat to Sarepta’s Elevidys.
November 19, 2024
·
2 min read
·
Tristan Manalac
Business
REGENXBIO Announces Leadership Transition
REGENXBIO Inc. announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024.
June 12, 2024
·
8 min read
BioCapital
REGENXBIO to Participate in Upcoming May 2024 Investor Conferences
REGENXBIO Inc. announced it will participate in the following upcoming investor conferences.
May 10, 2024
·
1 min read
BioCapital
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.
June 5, 2024
·
1 min read
Drug Development
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).
June 24, 2024
·
10 min read
Business
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO Inc. announced financial results for the first quarter ending March 31, 2024.
May 8, 2024
·
13 min read
BioCapital
REGENXBIO to Participate in Upcoming March 2024 Investor Conferences
REGENXBIO Inc. announced it will participate the following upcoming investor conferences.
March 11, 2024
·
1 min read
BioCapital
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
REGENXBIO Inc. (Nasdaq: RGNX) today announced it completed a successful Pre-Biologics License Application (BLA) meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II (MPS II), where it finalized details of its BLA with the U.S. Food and Drug Administration (FDA).
June 18, 2024
·
9 min read
BioCapital
REGENXBIO to Participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
REGENXBIO Inc. announced it will participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
April 24, 2024
·
1 min read
BioCapital
REGENXBIO to Participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
March 27, 2024
·
1 min read
1 of 48
Next
